These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 28735640)

  • 1. Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method.
    Rothe PH; Heres S; Leucht S
    Schizophr Res; 2018 Mar; 193():23-28. PubMed ID: 28735640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose equivalents for second-generation antipsychotics: the minimum effective dose method.
    Leucht S; Samara M; Heres S; Patel MX; Woods SW; Davis JM
    Schizophr Bull; 2014 Mar; 40(2):314-26. PubMed ID: 24493852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
    Leucht S; Crippa A; Siafis S; Patel MX; Orsini N; Davis JM
    Am J Psychiatry; 2020 Apr; 177(4):342-353. PubMed ID: 31838873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method.
    Leucht S; Samara M; Heres S; Patel MX; Furukawa T; Cipriani A; Geddes J; Davis JM
    Schizophr Bull; 2015 Nov; 41(6):1397-402. PubMed ID: 25841041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Guidelines for the use of second-generation long-acting antipsychotics].
    Jarema M; Wichniak A; Dudek D; Samochowiec J; Bieńkowski P; Rybakowski J
    Psychiatr Pol; 2015; 49(2):225-41. PubMed ID: 26093588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia.
    Park EJ; Amatya S; Kim MS; Park JH; Seol E; Lee H; Shin YH; Na DH
    Arch Pharm Res; 2013 Jun; 36(6):651-9. PubMed ID: 23543652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview.
    Correll CU; Kim E; Sliwa JK; Hamm W; Gopal S; Mathews M; Venkatasubramanian R; Saklad SR
    CNS Drugs; 2021 Jan; 35(1):39-59. PubMed ID: 33507525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison.
    Cameron C; Zummo J; Desai DN; Drake C; Hutton B; Kotb A; Weiden PJ
    Value Health; 2017; 20(7):876-885. PubMed ID: 28712616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia.
    Citrome L
    Expert Rev Neurother; 2013 Jul; 13(7):767-83. PubMed ID: 23898849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
    Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
    Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.
    Citrome L
    Expert Rev Clin Pharmacol; 2016; 9(2):169-86. PubMed ID: 26573020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose response and dose equivalence of antipsychotics.
    Davis JM; Chen N
    J Clin Psychopharmacol; 2004 Apr; 24(2):192-208. PubMed ID: 15206667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting injectable antipsychotics in the elderly: guidelines for effective use.
    Masand PS; Gupta S
    Drugs Aging; 2003; 20(15):1099-110. PubMed ID: 14651433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia.
    Hard ML; Mills RJ; Sadler BM; Turncliff RZ; Citrome L
    J Clin Psychopharmacol; 2017 Jun; 37(3):289-295. PubMed ID: 28350572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS).
    Novakovic V; Adel T; Peselow E; Lindenmayer JP
    Clin Neuropharmacol; 2013; 36(2):59-62. PubMed ID: 23503549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose Equivalents for Antipsychotic Drugs: The DDD Method.
    Leucht S; Samara M; Heres S; Davis JM
    Schizophr Bull; 2016 Jul; 42 Suppl 1(Suppl 1):S90-4. PubMed ID: 27460622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required?].
    Charpeaud T; Samalin L; Llorca PM
    Encephale; 2014 Feb; 40(1):62-73. PubMed ID: 24445245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.